Exhibit
32.2
Certification
of Chief Financial Officer
Pursuant
to 18 U.S.C Section 1350,
As
Adopted Pursuant to Section 906 of the
Sarbanes-Oxley
Act of 2002
Not Filed
Pursuant to the Securities Exchange Act of 1934
In
connection with the Quarterly Report of Ohr Pharmaceutical, Inc (the “Company”) on Form 10Q for
the period ending December 31, 2009, as filed with the Securities and Exchange
Commission on the date hereof )the “Report”), I, Andrew Limpert, Chief Financial Officer, and
Secretary/Treasurer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:
| 1. |
The
Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and |
| |
|
| 2. |
The
information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company. |
| |
|
|
| |
|
|
|
|
Date
February 16, 2010
|
By:
|
/s/ Andrew
Limpert |
|
| |
|
Name Andrew
Limpert |
|
| |
|
Title Interim
Chief Financial Officer |
|
| |
|
|
|